IL307430A - Methods for treating cancer with subcutaneous administration of ANTI-PD1 antibodies - Google Patents

Methods for treating cancer with subcutaneous administration of ANTI-PD1 antibodies

Info

Publication number
IL307430A
IL307430A IL307430A IL30743023A IL307430A IL 307430 A IL307430 A IL 307430A IL 307430 A IL307430 A IL 307430A IL 30743023 A IL30743023 A IL 30743023A IL 307430 A IL307430 A IL 307430A
Authority
IL
Israel
Prior art keywords
cancer
patient
antibody
seq
binding fragment
Prior art date
Application number
IL307430A
Other languages
English (en)
Hebrew (he)
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of IL307430A publication Critical patent/IL307430A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL307430A 2021-04-08 2022-04-04 Methods for treating cancer with subcutaneous administration of ANTI-PD1 antibodies IL307430A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163172299P 2021-04-08 2021-04-08
PCT/US2022/023250 WO2022216580A1 (en) 2021-04-08 2022-04-04 Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies

Publications (1)

Publication Number Publication Date
IL307430A true IL307430A (en) 2023-12-01

Family

ID=83546458

Family Applications (1)

Application Number Title Priority Date Filing Date
IL307430A IL307430A (en) 2021-04-08 2022-04-04 Methods for treating cancer with subcutaneous administration of ANTI-PD1 antibodies

Country Status (21)

Country Link
US (1) US20250074983A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320163A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513247A (cg-RX-API-DMAC7.html)
KR (1) KR20230170029A (cg-RX-API-DMAC7.html)
CN (1) CN117279952A (cg-RX-API-DMAC7.html)
AR (1) AR125296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022254960A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020867A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214617A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002976A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013273A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230473A (cg-RX-API-DMAC7.html)
DO (2) DOP2023000216A (cg-RX-API-DMAC7.html)
EC (1) ECSP23076276A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416385A (cg-RX-API-DMAC7.html)
IL (1) IL307430A (cg-RX-API-DMAC7.html)
JO (1) JOP20230243A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011857A (cg-RX-API-DMAC7.html)
PE (1) PE20240051A1 (cg-RX-API-DMAC7.html)
TW (1) TW202305009A (cg-RX-API-DMAC7.html)
WO (1) WO2022216580A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
WO2025140467A1 (zh) * 2023-12-29 2025-07-03 上海复宏汉霖生物技术股份有限公司 稳定的高浓度抗pd-1抗体药物制剂
WO2026124472A1 (zh) * 2024-12-10 2026-06-18 四川科伦博泰生物医药股份有限公司 治疗组合及其用途和治疗方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3634484A4 (en) * 2017-06-05 2022-01-12 The Council of the Queensland Institute of Medical Research A COMBINATION OF OR A BI-SPECIFIC BINDING MOLECULE TO AN IMMUNOCONTROL MOLECULE ANTAGONIST AND A RANK-L (NF-κB-LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN112203642B (zh) * 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物

Also Published As

Publication number Publication date
DOP2026000117A (es) 2026-07-31
ECSP23076276A (es) 2023-11-30
EP4320163A1 (en) 2024-02-14
TW202305009A (zh) 2023-02-01
CA3214617A1 (en) 2022-10-13
WO2022216580A1 (en) 2022-10-13
MX2023011857A (es) 2023-10-19
CO2023013273A2 (es) 2023-10-30
GEAP202416385A (en) 2024-02-26
JP2024513247A (ja) 2024-03-22
AU2022254960A1 (en) 2023-11-23
EP4320163A4 (en) 2025-03-05
JOP20230243A1 (ar) 2023-10-08
CN117279952A (zh) 2023-12-22
CL2023002976A1 (es) 2024-06-28
PE20240051A1 (es) 2024-01-09
US20250074983A1 (en) 2025-03-06
KR20230170029A (ko) 2023-12-18
AU2022254960A9 (en) 2023-11-30
DOP2023000216A (es) 2023-11-30
BR112023020867A2 (pt) 2023-12-12
AR125296A1 (es) 2023-07-05
CR20230473A (es) 2023-11-30

Similar Documents

Publication Publication Date Title
JP2024102215A5 (cg-RX-API-DMAC7.html)
Henricks et al. The use of combinations of monoclonal antibodies in clinical oncology
JP2020508317A5 (cg-RX-API-DMAC7.html)
IL321717A (en) Anti-PD-1 antibodies for the treatment of lung cancer
JP2023511595A5 (cg-RX-API-DMAC7.html)
JP2021513541A5 (cg-RX-API-DMAC7.html)
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
RU2015149285A (ru) Схемы дозирования иммуноконъюгата anti-folr1
JP2021513540A5 (cg-RX-API-DMAC7.html)
WO2022174775A1 (en) Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer
JP2024545428A5 (cg-RX-API-DMAC7.html)
JP2023539589A5 (cg-RX-API-DMAC7.html)
JP2023548430A5 (cg-RX-API-DMAC7.html)
IL320229A (en) Compositions and methods for treating cancer with subcutaneous administration of anti-pd1 antibodies
JP2024513247A5 (cg-RX-API-DMAC7.html)
JP2023537222A5 (cg-RX-API-DMAC7.html)
JPWO2022270524A5 (cg-RX-API-DMAC7.html)
RU2017142804A (ru) Лечение пациентов с диагнозом аденокарцинома поджелудочной железы с использованием моноклональных антител к рецептору эпидермального фактора роста (egfr)
CR20230473A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.
JP2022530599A5 (cg-RX-API-DMAC7.html)
JP2024536383A5 (cg-RX-API-DMAC7.html)
JP2025502061A5 (cg-RX-API-DMAC7.html)
JP2024519450A5 (cg-RX-API-DMAC7.html)
CN110013552B (zh) 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途
JP2024538755A5 (cg-RX-API-DMAC7.html)